These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Retreatment with talimogene laherparepvec for advanced melanoma. Hu J; Masoud SJ; Ravichandran S; Beasley GM; Mosca PJ Immunotherapy; 2020 Nov; 12(16):1167-1172. PubMed ID: 32840157 [No Abstract] [Full Text] [Related]
4. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab. Afzal MZ; Shirai K J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044 [TBL] [Abstract][Full Text] [Related]
5. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. Sun L; Funchain P; Song JM; Rayman P; Tannenbaum C; Ko J; Mcnamara M; Marcela Diaz-Montero C; Gastman B J Immunother Cancer; 2018 May; 6(1):36. PubMed ID: 29764498 [TBL] [Abstract][Full Text] [Related]
6. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039 [TBL] [Abstract][Full Text] [Related]
7. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey. Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143 [TBL] [Abstract][Full Text] [Related]
8. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650 [TBL] [Abstract][Full Text] [Related]
9. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293 [TBL] [Abstract][Full Text] [Related]
10. An evaluation of talimogene laherparepvec for the treatment of melanoma. Broman KK; Zager JS Expert Opin Biol Ther; 2020 Jan; 20(1):9-14. PubMed ID: 31690129 [No Abstract] [Full Text] [Related]
11. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model. Stahlie EHA; Franke V; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ Cancer Immunol Immunother; 2021 Aug; 70(8):2291-2300. PubMed ID: 33507342 [TBL] [Abstract][Full Text] [Related]
12. False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC). Mulder EEAP; Stahlie EHA; Verver D; Lemstra C; Been LB; Mooyaart AL; Brabander T; Vegt E; Verburg FA; van der Veldt AAM; Verhoef C; van Akkooi ACJ; Grünhagen DJ J Surg Oncol; 2021 Dec; 124(7):1161-1165. PubMed ID: 34235758 [TBL] [Abstract][Full Text] [Related]
13. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. Kelly CM; Antonescu CR; Bowler T; Munhoz R; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Dholakia R; Ahmad H; Biniakewitz M; Condy M; Phelan H; Callahan M; Wong P; Singer S; Ariyan C; Bartlett EK; Crago A; Yoon S; Hwang S; Erinjeri JP; Qin LX; Tap WD; D'Angelo SP JAMA Oncol; 2020 Mar; 6(3):402-408. PubMed ID: 31971541 [TBL] [Abstract][Full Text] [Related]
14. Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115. Robert C; Gastman B; Gogas H; Rutkowski P; Long GV; Chaney MF; Joshi H; Lin YL; Snyder W; Chesney JA Eur J Cancer; 2024 Aug; 207():114120. PubMed ID: 38870745 [TBL] [Abstract][Full Text] [Related]
15. Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis. Stahlie EHA; Mulder EEAP; Reijers S; Balduzzi S; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; Grunhagen DJ; van Akkooi ACJ Crit Rev Oncol Hematol; 2022 Jul; 175():103705. PubMed ID: 35569723 [TBL] [Abstract][Full Text] [Related]
16. Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany. Ressler JM; Karasek M; Koch L; Silmbrod R; Mangana J; Latifyan S; Aedo-Lopez V; Kehrer H; Weihsengruber F; Koelblinger P; Posch C; Kofler J; Michielin O; Richtig E; Hafner C; Hoeller C J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608376 [TBL] [Abstract][Full Text] [Related]
17. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries. van Akkooi ACJ; Haferkamp S; Papa S; Franke V; Pinter A; Weishaupt C; Huber MA; Loquai C; Richtig E; Gokani P; Öhrling K; Louie KS; Mohr P Adv Ther; 2021 Feb; 38(2):1245-1262. PubMed ID: 33368016 [TBL] [Abstract][Full Text] [Related]
18. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Andtbacka RH; Ross M; Puzanov I; Milhem M; Collichio F; Delman KA; Amatruda T; Zager JS; Cranmer L; Hsueh E; Chen L; Shilkrut M; Kaufman HL Ann Surg Oncol; 2016 Dec; 23(13):4169-4177. PubMed ID: 27342831 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial. Rohaan MW; Stahlie EHA; Franke V; Zijlker LP; Wilgenhof S; van der Noort V; van Akkooi ACJ; Haanen JBAG BMC Cancer; 2022 Aug; 22(1):851. PubMed ID: 35927710 [TBL] [Abstract][Full Text] [Related]